Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients

Introduction: Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies, especially under therapy with monoclonal antibodies targeting B-cells. Herein, we evaluated the development of neutralizing antibodies (NAbs) against SARS-CoV-2 in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Gavriatopoulou, Maria, Fotiou, Despina, Giatra, Chara, Asimakopoulos, John V., Dimou, Maria, Sklirou, Aimilia D., Ntanasis-Stathopoulos, Ioannis, Darmani, Ismini, Briasoulis, Alexandros, Kastritis, Efstathios, Angelopoulou, Maria K., Baltadakis, Ioannis, Panayiotidis, Panayiotis, Trougakos, Ioannis P., Vassilakopoulos, Theodoros P., Pagoni, Maria, Dimopoulos, Meletios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
642.Chronic Lymphocytic Leukemia: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701546/
http://dx.doi.org/10.1182/blood-2021-145110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701546/
http://dx.doi.org/10.1182/blood-2021-145110

Ejemplares similares